To estimate the cost-effectiveness of low-molecular-weight heparin (LMWH) in the treatment of proximal lower extremity deep venous thrombosis.
A pproximately 2 million new cases of venous thromboembolism occur each year in the United States. 1 Among patients adequately treated, thromboembolism may recur in up to 30% at 8 years, and the postphlebitic syndrome may develop in up to 28% at 5 years. 2 Hospitalization and treatment with high-dose unfractionated heparin (UH) is the standard treatment for patients with deep venous thrombosis and pulmonary embolism. 1, [3] [4] [5] [6] [7] Low-molecular-weight heparin (LMWH) is as effective as UH in the treatment of venous thromboembolism. [8] [9] [10] [11] [12] [13] [14] In some studies, patients treated with LMWH had fewer episodes of recurrent thromboembolism, major bleeding, and heparin-induced thrombocytopenia. 1, [8] [9] [10] 15 The LMWHs have recently been approved to treat venous thrombosis in the United States. In some European countries up to 24% of patients are treated with LMWH. 2 Though LMWH is 5 to 10 times more expensive than UH, it has three principal advantages: LMWH is administered subcutaneously, monitoring its anticoagulation effect is not necessary in most patients, 16 and it gives the potential for treating patients at home. 11, 12 The cost of treating all patients with LMWH poses a unique problem to hospitals reimbursed on an episode-ofcare basis. Such hospitals have strong financial disincentives for the routine use of LMWH. However, a hospital or health care system at risk for the long-term costs of caring for a defined population in a capitated system would have an incentive to treat patients at home with LMWH. In the latter example, the concern is that managed care companies may impose pressure on physicians to treat patients at home who indeed require hospitalization. In both cases, patients who cannot be treated at home might receive UH as it minimizes costs. Institutions with fixed and separate budgets for pharmacy, hospital care, and home care may have difficulties deciding which heparin to use. In this example, the pharmacy has no interest in future costs and would suggest the least-expensive alternative. In any of these examples, the selective use of LMWH for patients eligible for home treatment may emerge as a good intermediate solution.
Economic evaluation within clinical trials has shown the benefits of the use of LMWH in the treatment of venous thrombosis. [17] [18] However, the care of patients participating in clinical trials may be so atypical that such results cannot be extrapolated to other settings. [19] [20] We use cost-effectiveness analysis (CEA) [21] [22] [23] [24] to understand the clinical benefit (or harm) and the cost (or savings) of different strategies in the treatment of deep venous thrombosis under usual clinical practice. In this work, we address the following questions: Is LMWH cost-effective in the treatment of deep venous thrombosis compared with UH? And if so, how does the selective use of UH for hospitalized patients or LMWH for patients treated at home compare with LMWH for all?
METHODS

Decision Model
We constructed a decision model in which a cohort of 1,000 hypothetical patients with proximal deep venous thrombosis of the lower extremity could receive intravenous UH, or LMWH, or intravenous UH for patients who require hospitalization and LMWH for patients treated at home (selective UH/LMWH) (Fig. 1) . We specified costs and benefits from the health care system (payer) perspective. We compared costs, recurrence of thromboembolism, death, and marginal cost-effectiveness ratios among the strategies. 23 Marginal cost-effectiveness ratio is expressed as the net cost incurred (or saved) per each additional (or prevented) clinical outcome. This cost-effectiveness ratio is obtained by the formula: (Cost-Effectiveness Ratio) ϭ (Net Cost)/ (Net Outcome), where (Net Cost) ϭ (Cost Treatment A) Ϫ (Cost Treatment B), and (Net Outcome) ϭ (Outcome B) Ϫ (Outcome A). A treatment is "dominant" if it costs less and has better outcomes, which is the most desirable situation.
During treatment with heparin, patients may develop pulmonary embolism, major bleeding, or heparin-induced thrombocytopenia for which they require a vena cava interruption procedure. Major bleed is defined as a decrease in hemoglobin of at least 2 g/dL, bleed located in the cranium, retroperitoneum, or prosthetic joint, or a bleed resulting in transfusion of at least 2 U of blood. 3 We assume that some patients die from such complications. We assume that patients receive anticoagulants for 3 months (time period used on most trials). During this period, patients have a probability of developing a recurrent venous thrombosis and dying from it (primarily from pulmonary embolism). Estimates of values for the base case and the range for sensitivity analysis are shown in Table 1 . In the base-case analysis, we assume that 40% of patients in the LMWH or selective UH/LMWH strategies are treated at home. In clinical trials, 35% to 70% of patients were eligible for home treatment. [11] [12] [13] We assume that 30% of such patients are never hospitalized (36%-48% in research settings) and the rest stay in the hospital for 2.5 days (2.2 Ϯ 3.8 days in research settings). 11, 12 We assume 6 days of treatment with UH or LMWH; in practice, patients received heparin for 5.5 to 6.5 days. [11] [12] [13] 
Sensitivity Analysis
We varied all probabilities and cost estimates in the sensitivity analysis. Sensitivity analysis tests the robustness of conclusions to variations in base-case estimates. 51 In oneway sensitivity analyses, the estimates were each modified, one at a time, while maintaining the other values at the base-case value. We also performed two-way sensitivity analysis and considered best-case and worst-case scenarios.
Probabilities
Estimates for recurrent thromboembolism, pulmonary embolism, death, major bleeding, and heparininduced thrombocytopenia were obtained from metaanalyses [8] [9] [10] 25, 27 and other reports ( 8 but not others (RR 0.85; 95% CI 0.63-1.14). 27 We assume that the various LMWHs are similar in effectiveness.
Costs
We include direct medical costs to treat the initial episode of deep venous thrombosis, major bleed, heparininduced thrombocytopenia, pulmonary embolism, and recurrent thromboembolism (see Table 1 and Appendix). To address the issue of cost shifting to patients, we assume that the direct cost of care at home is paid by the health system. Cost data were derived from cost accounting at our institution for each of the services rendered (charge data were not used for our estimates). Cost to Medicare was used as a proxy for physicians' fees for professional services. All monetary values are in 1996 U.S. FIGURE 1. Decision tree. UH indicates unfractionated heparin; LMWH, low-molecular-weight heparin.
dollars. We excluded the fixed costs of hospital care, focusing only on the relevant variable costs associated with the choice of drugs and dosage. Our cost estimates to treat an episode of deep venous thrombosis, major bleed, and pulmonary embolism are similar to those in the published literature. We used Data 3.0.17 to calculate cost-effectiveness data (TreeAge Software, Inc, Williamston, Mass).
Assumptions
We assume that recurrent thromboembolism occurs only once within 3 months. We do not include costs or outcomes associated with minor bleed, emergency department visits, and warfarin monitoring because we assume them to be equal among the strategies. We assume that the probability of death after a recurrent thromboembolism was the same between patients who did and patients who did not sustain a complication during the hospital stay (pulmonary embolism, bleed, and heparin-induced thrombocytopenia). Data support the assumption that mortality after a recurrent thromboembolism is higher in patients who present with pulmonary embolism, 28,31 as compared with deep venous thrombosis of the legs. We assume that mortality was similar among treatment options. Some meta-analyses have shown survival advantage among LMWH-treated patients, 8, 27 and others have not. 10, 25 By not including these variables, we may underestimate the benefits of the LMWH. We assume that the cost of recurrent thrombosis is equal to the cost of treatment of the initial episode (additional costs incurred owing to pulmonary embolism modeled in the sensitivity analysis). We do not discount costs or outcomes as the outcomes are expected to occur within 3 months. Postphlebitic syndrome was not included as an outcome as it occurs beyond the time frame of our analysis and there are no long-term data to examine it.
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RESULTS
Base Case
The base-case clinical outcomes and costs per 1,000 patients treated are shown in Table 2 . The LMWH strategy dominates the UH strategy; i.e., 16.7 fewer cases of recurrent thromboembolism and 2 fewer deaths occur, saving the health care system $310,765.
The selective UH/LMWH strategy also dominates the UH strategy; i.e., 6.7 fewer cases of recurrent thromboembolism and 0.8 fewer deaths occur, saving the health care system $407,587.
The LMWH strategy does not dominate the selective UH/LMWH strategy. It results in 10 fewer cases of recurrent thromboembolism and 1.2 fewer deaths, but at an additional cost to the health care system of $96,822. The costeffectiveness ratios of the LMWH strategy as compared with the selective UH/LMWH strategy are $9,667 and $80,685 per recurrent thromboembolism or death prevented, respectively. Most of the savings occurred during the treatment of the index case by decreasing the length of stay.
Sensitivity Analysis
Under the assumption of equal effectiveness for recurrent thromboembolism, the LMWH strategy and the selective UH/LMWH strategies were $269,492 and $395,262 less expensive than the UH strategy (per 1,000 patients treated), respectively.
Recurrent thromboembolism and mortality were insensitive to any assumptions in one-way sensitivity analyses. The LMWH strategy always resulted in fewer cases of thromboembolism and deaths than the UH strategy or the selective UH/LMWH strategy. Threshold analysis showed that the LMWH strategy led to fewer cases of recurrent thromboembolism or deaths at relative risks of recurrent thromboembolism of less than 1.02 (Fig. 2) or less than 1.11, respectively. The total cost of treatment was insensitive to the relative risk of recurrent thromboembolism. The cost was higher for the UH strategy, followed by the LMWH strategy, and then by the selective UH/LMWH strategy ( Figure 2) .
In one-way sensitivity analysis, the LMWH strategy always resulted in lower costs than the UH strategy, unless the proportion of eligible patients for home treatment was less than 14% (base case, 40%), or patients who received LMWH remained hospitalized for more than 6.5 days (base case, 2.5 days). In one-way sensitivity analysis, the LMWH strategy always resulted in higher costs than the selective UH/LMWH strategy, unless the cost of treatment with UH was more than $3,018 (base case, $2,376). The costs of treatment and clinical outcomes per 1,000 patients treated in two-way sensitivity analysis are shown in Table 3 . The LMWH strategy was dominant over the UH strategy when the relative risk of recurrent thromboembolism was less than 1 and the proportion of patients eligible for home therapy was as low as 14%. The LMWH strategy resulted in higher costs and fewer cases of recurrent thromboembolism or death than the selective UH/LMWH strategy.
DISCUSSION
Our analysis suggests that at the base case or at any given range of assumptions, treating patients with proximal deep venous thrombosis with LMWH will result in fewer cases of recurrent thromboembolism or deaths within 3 months as compared with the selective UH/LMWH strategy or the UH strategy. The LMWH and the selective UH/LMWH strategies dominated the UH strategy; i.e., they resulted in fewer adverse clinical outcomes and saved resources of the health care system. The decrease in costs originated primarily by a decrease in the length of stay.
Economic evaluation and clinical trials provide the best source of data regarding the efficacy of an intervention in research settings. 19 Such economic analyses are able to measure directly the costs of interventions and outcomes. However, the care of patients participating in clinical trials may be so atypical that such results cannot be extrapolated to other settings. 19 Differences in operational efficiency of systems and institutions participating in clinical trials may differ significantly from usual practice. 20 Also, it may be difficult to decide whether other interventions, tests, or services are carried out because of the research protocol or the usual treatment. 20 Confirming results from such economic evaluations with CEA may provide convergent validity on the use of LMWH. The economic evaluation of treating patients with deep venous thrombosis with LMWH as compared with UH has been published for two clinical trials, 17, 18 one cost minimization study, 41 and two cost-effectiveness analyses. 52, 53 Hull et al. showed that the LMWH strategy (tinzaparin, RR of recurrent thrombosis of 41%) dominates the UH strategy; i.e., 41 fewer cases of recurrent thromboembolism and 49 fewer deaths occur per 1,000 patients treated, saving the health care system $482,000 17 (all patients hospitalized, data calculated from the report and converted to 1996 U.S. dollars by using the Consumer Price Index for medical care). The savings would have increased to $1,096,370 if 37% of patients had been treated outside the hospital setting. The second report showed a 64% reduction in cost (95% CI 56%-72%), primarily due to a 40% reduction in length of stay. 18 The latter clinical trial evaluated nadroparin and found a nonsignificant 20% risk reduction of recurrent thrombosis. 12 The costminimization study performed in Germany estimated savings of $1,687,820 per 1,000 patients treated with LMWH as compared with UH. 41 The authors assumed similar efficacy and side effects, hospital stay of 2.7 days for all patients who receive LMWH and 8.1 days for patients receiving UH, and 15% of patients requiring a skilled nursing visit, and two visits to the physician. Gould et al. found that LMWH is highly cost-effective for the management of deep venous thrombosis. 52 The LMWH strategy dominated the UH strategy; cost savings were realized at the same time as lower mortality. The authors used the societal perspective and the patient's lifetime as the analytic horizon. They assumed 30% of patients receiving LMWH at home and 25% discharged from the hospital after 3 days. The second cost-effectiveness analysis using the third-party payer and an analytic horizon of 3 months also showed that the LMWH strategy dominates the UH strategy. 53 Our CEA extends the results of prior reports 17,18,41,52,53 in several ways. First, by modeling the benefits and risks of LMWH using a different approach, we reach similar conclusions that the use of LMWH results in better outcomes at a lower cost; however, our estimates of savings are more conservative. Second, not every patient is a candidate for treatment at home with LMWH. The selective use of UH for hospitalized patients or LMWH for patients treated at home is an attractive option for institutions with limited pharmacy budgets, or until more data become available supporting the improved outcomes in patients who receive any of the LMWH. We chose to model three strategies and acknowledge that the selective UH/LMWH is a combined approach of the UH and LMWH strategies. The cost-effectiveness ratio of LMWH versus selective UH/LMWH reflects the differences between inpatient LMWH and inpatient UH (costs and health effects cancel out in the 40% of those in each cohort treated as outpatients with LMWH). And third, this CEA may allow consumers, policymakers, and administrators to model and understand the trade-offs between strategies. This is important when the relative effectiveness of interventions, percentage of patients eligible for treatment at home, operational efficiencies of institutions, and reimbursement structure vary under usual clinical practice. Our analysis is consistent with others. 52, 53 The potential improvement in clinical outcomes and cost savings are illustrated in the sensitivity analysis. Some studies have reported that the effectiveness and risks of using LMWH are similar to those of UH [10] [11] [12] ; even under these equal effectiveness assumptions, the LMWH dominates the UH strategy. Savings should occur even when as few as 14% of patients who receive LMWH are treated at home (base case, 40%). Our findings do not change across a wide range of values used for relative risk of recurrent thromboembolism, major bleeding, heparin-induced thrombocytopenia, hospitalization rates, length of hospitalization, duration of therapy, and LMWH cost, among others.
Some aspects in the interpretation of this study are worth emphasizing. First, we assumed that all LMWHs are equally effective. We varied the effectiveness of the LMWH in the sensitivity analysis to include such uncertainty. Second, patients with suspected pulmonary embolism or recurrent thrombosis were not modeled to receive LMWH. Results of recent trials of LMWH in patients with deep venous thrombosis and pulmonary embolism are promising. 13, 14, 54 Third, we assumed that mortality was similar among treatment options, and we may have underestimated the effectiveness of the LMWH. A recent meta-analysis showed a lower mortality among LMWH-treated patients (RR 0.71; 95% CI 0.53-0.94). 27 However, no firm data exist on this survival advantage among patients treated at home. Finally, in research settings, 35% to 70% of patients were eligible for outpatient treatment and 36% to 48% of patients were never hospitalized, 11-13 whereas we assumed 40% and 30%, respectively. Our assumptions would not apply to health care systems that are not prepared to care for these patients at home. Clinically unstable patients or patients at risk of developing pulmonary embolism, thrombocytopenia, or bleeding should still be hospitalized. The savings by decreasing the length of stay may seem obvious; however, cost shifting to ambulatory facilities and patients needs to be addressed before a widespread policy of treating patients at home is implemented.
In conclusion, LMWH appears to be the treatment of choice for patients with deep venous thrombosis in whom pulmonary embolism is not suspected. However, for patients who require hospitalization, the use of intravenous UH is an alternative option.
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